Peptide

ACE-083

Also known as

ACE083 · local follistatin ligand trap · Acceleron ACE-083

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	An experimental follistatin-based protein designed to block muscle-growth brakes in the injected muscle.
Why people look it up	Growing lagging calves or arms. ACE-031, Follistatin 344 and FLGR-242 are different products.

Notes

ACE-083 attracts people hoping to grow a particular muscle, especially lagging calves or arms. It is an experimental follistatin-based protein designed for local muscle injection. Clinical muscle-volume gains did not consistently improve function; interest in bodybuilding does not establish dependable gym results.

A local trap for muscle-growth brakes. The engineered protein binds signaling molecules, including myostatin and activins, that restrain muscle growth. Its design aims to keep activity in the injected muscle and rapidly inactivate drug reaching the bloodstream. That describes the studied medicine's design. Glasser et al.: Locally acting ACE-083 increases muscle volume in healthy volunteers (Official context · Accessed 2026-09-30)

The names are not interchangeable. ACE-031, Follistatin 344, FLGR-242 and ACE-083 recur in the same conversations. The preserved comparison describes ACE-031 as a receptor decoy and FLGR as a claimed systemic, albumin-bound product. Their charts and risk stories do not automatically describe ACE-083. It is also different from follistatin gene therapy.

Source context — Glasser et al.: Locally acting ACE-083 increases muscle volume in healthy volunteers: Healthy postmenopausal women receiving trial material; not online-vial authentication or human community kinetics. Systemic samples largely below measurement limit do not measure drug retention half-life inside muscle. Sponsor-employed authors. PMC access intermittently returned CAPTCHA; Wiley full text used.

What people notice

Muscle growth reports	The inspected gym accounts do not show a measured growth or strength result. One biceps user reported a bruised feeling overnight.
Trial results	Injected-muscle volume increased, but everyday function did not reliably improve. Both disease programs were discontinued.

Notes

A use claim can still leave identity and results unanswered. The 2023 forum author's doubt about legitimacy accompanies the fortnightly amount. They also describe IGF-1 products, growth hormone and treatment for high blood sugar. No isolated ACE-083 result follows in the inspected posts; a board representative's enthusiasm is separate advocacy. Latest in future drug discovery: myostatin inhibitors & more (Personal report · Accessed 2026-09-30)

The biceps update is one person, not corroboration. The same day-one update appears in the post and a comment. Later readers ask for a conclusion, but no outcome is visible. Another reply identifies testosterone as a confounder. Reported formulation difficulty adds uncertainty rather than a preparation method. Anyone familiar with ACE-083 research with test? (Personal report · Accessed 2026-09-30)

Soreness after use; growth onset remains unknown. The biceps author reports a bruised feeling after first use that remains overnight, without a measured start date for muscle growth or strength improvement. Anyone familiar with ACE-083 research with test? (Personal report · Accessed 2026-09-30)

Size and everyday function did not reliably improve together. The CMT study increased volume but lacked broad motor or quality-of-life benefit. Its development program was discontinued, as was FSHD's. This does not resolve healthy-lifter outcomes. Thomas et al.: Randomized phase 2 ACE-083 study in Charcot-Marie-Tooth disease (Official context · Accessed 2026-09-30) · Statland et al.: Randomized phase 2 ACE-083 study in FSHD (Official context · Accessed 2026-09-30)

Source context — Latest in future drug discovery: myostatin inhibitors & more: ACE-083 route and result unstated. Multiple co-used drugs prevent attribution. Board-representative promotion is not an independent use result. Contact, procurement and co-use numeric recipe excluded.

Source context — Anyone familiar with ACE-083 research with test?: One unverified product experiment with concurrent testosterone. Weekly opening plan differs from later per-biceps 14-day plan. No growth conclusion visible; duplicated update is one account. Preparation/procurement details excluded. Opening date 2025-11-14 appears in indexed date labels; explicit update date is in body.

Source context — Thomas et al.: Randomized phase 2 ACE-083 study in Charcot-Marie-Tooth disease: CMT1/CMTX patients; one manual-strength signal does not overturn absence of broad functional benefit. 47.8% anti-drug antibodies is study-phase-specific. Neurology direct access failed; PMC CAPTCHA; repository PDF body inspected instead.

Source context — Statland et al.: Randomized phase 2 ACE-083 study in FSHD: FSHD participants and sponsor-funded medicine program; no prediction for healthy lifters, FLGR or product identity. Muscle volume endpoint improved, functional/PRO outcomes inconsistent; program discontinued. Antibody percentages are from double-blind part2, not prevalence among gym users.

Doses people talk about

Fortnightly account	1 mg every two weeks; route and results were unstated, and the poster doubted the product was genuine.
Biceps log	Opening plan: 1 mg/week with testosterone. Later update: 1 mg IM per biceps, 2 mg total that day, with a repeat planned 14 days later.
Adverse report	40 mg at first use, route unstated, accompanied a severe reaction. It is not a useful dose target.
Formal trial amounts	FSHD escalation tested 150–200 mg per muscle and 240 mg in biceps; randomized treatment used 240 mg per muscle every three weeks. These are disease-trial amounts.

Notes

1 mg every two weeks in a 2023 forum account. The poster does not specify the ACE-083 route or report an attributable result. Their authenticity concern and extensive co-use limit interpretation. Latest in future drug discovery: myostatin inhibitors & more (Personal report · Accessed 2026-09-30)

A biceps log changed its stated plan. The opening proposes 1 mg/week alongside testosterone 300 mg/week, both split twice weekly. The December 8 update instead reports 1 mg IM per biceps, 2 mg total that day, with another administration planned 14 days later. These are not the same schedule. Anyone familiar with ACE-083 research with test? (Personal report · Accessed 2026-09-30)

40 mg in an adverse-reaction account. A different commenter describes this amount at first use, without specifying route. It belongs to an adverse report, not evidence that larger amounts work better. Has anyone tried ACE-031? selective and site-specific myostatin inhibitor (Community discussion · Accessed 2026-09-30)

A local design does not guarantee a mild reaction. The 40 mg commenter describes severe shaking, chills and high temperature, then questions authenticity. This cannot prove whether genuine ACE-083, contamination or something else caused the reaction. Their later improvement does not establish safety. Has anyone tried ACE-031? selective and site-specific myostatin inhibitor (Community discussion · Accessed 2026-09-30)

Trial milligrams belonged to defined muscles and patients. FSHD dose-escalation used 150 or 200 mg per muscle; biceps also tested 240 mg. Randomized treatment used 240 mg per muscle every three weeks for six months before open-label treatment. Statland et al.: Randomized phase 2 ACE-083 study in FSHD (Official context · Accessed 2026-09-30)

Source context — Has anyone tried ACE-031? selective and site-specific myostatin inhibitor: Mixed-compound thread. Opening poster's ACE-031 flu symptoms and other replies' ACE-031 research quantities are not ACE-083 evidence. ACE-083 route, authentication and reaction cause unverified. Only relative dates on opened page; exact comment publication date unknown. Speculative relative-safety and cell-number theories not adopted.

Half-life, onset & duration

Felt onset	Muscle-growth onset is unknown. One biceps user described soreness after first use that remained overnight.
Felt duration	No lasting benefit window is established. One severe-reaction account improved after two to three hours; that is symptom duration.
Half-life	Not established in the saved community record. Low blood levels in the local-injection trial do not measure how long drug remains in muscle.

Notes

No established lasting benefit in these accounts. The severe-reaction commenter says symptoms improved after two to three hours. That symptom history does not measure benefit duration or whether muscle gained during use persists after stopping. Has anyone tried ACE-031? selective and site-specific myostatin inhibitor (Community discussion · Accessed 2026-09-30)

No dependable community human value. Half-life asks how quickly the measured amount falls by half. The community record does not establish that value for ACE-083. A repeat schedule cannot supply it; the preserved comparison warns against importing a 19-day FLGR number.

Mostly unmeasurable blood drug is not a muscle half-life. Healthy-volunteer serum testing supported low systemic exposure. It did not establish how long drug remained inside the muscle or a community benefit window. Glasser et al.: Locally acting ACE-083 increases muscle volume in healthy volunteers (Official context · Accessed 2026-09-30)

Cycles people discuss

Community courses	Fortnightly use and repeat plans appear, without a completed course, time-off schedule or post-stop result.

Notes

Repeat intentions, without a completed course. Fortnightly use or a planned repeat does not establish total course length, time off or a post-stop result. Neither account supplies those answers. Clinical treatment periods cannot supply a bodybuilding cycle. Latest in future drug discovery: myostatin inhibitors & more (Personal report · Accessed 2026-09-30) · Anyone familiar with ACE-083 research with test? (Personal report · Accessed 2026-09-30)

Stacks

Testosterone	The biceps log also used testosterone, so it cannot separate any ACE-083 effect.
IGF-1 and growth hormone	The fortnightly user also described IGF-1 products and growth hormone, without an isolated ACE-083 result.

Notes

Watch for

Severe reaction	One unverified 40 mg account describes shaking, chills and high temperature. The cause and product identity were unresolved.
Trial immune reactions	Anti-drug antibodies occurred in 39.3% of FSHD recipients and 47.8% in CMT; swelling, pain and nerve symptoms also appeared in FSHD.
Combination uncertainty	The FSHD trial excluded androgens and growth hormone. It does not establish the safety of the combinations reported online.

Notes

The trials reported immune responses and local problems. Antibodies recognizing the study drug appeared in 39.3% of ACE-083 recipients in the FSHD double-blind phase and 47.8% in CMT. FSHD also recorded swelling, pain and nerve symptoms. These findings do not establish why an online user reacted. Statland et al.: Randomized phase 2 ACE-083 study in FSHD (Official context · Accessed 2026-09-30) · Thomas et al.: Randomized phase 2 ACE-083 study in Charcot-Marie-Tooth disease (Official context · Accessed 2026-09-30)

Stack safety and long-term use remain unresolved. The FSHD trial excluded pregnancy and use of androgens or growth hormone. Its supervised findings cannot certify those combinations, pregnancy use or prolonged unsupervised use. Statland et al.: Randomized phase 2 ACE-083 study in FSHD (Official context · Accessed 2026-09-30)

Full notes

What ACE-083 actually is

A local trap for muscle-growth brakes. The engineered protein binds signaling molecules, including myostatin and activins, that restrain muscle growth. Its design aims to keep activity in the injected muscle and rapidly inactivate drug reaching the bloodstream. That describes the studied medicine's design. Official context
The names are not interchangeable. ACE-031, Follistatin 344, FLGR-242 and ACE-083 recur in the same conversations. The preserved comparison describes ACE-031 as a receptor decoy and FLGR as a claimed systemic, albumin-bound product. Their charts and risk stories do not automatically describe ACE-083. It is also different from follistatin gene therapy. Community

What people hope to gain

More size where training has disappointed them. A bodybuilding question, cross-posted to Biohacking, asks about disproportionately slow calves and shoulder development. Replies divide between enthusiasm for growth compounds and skepticism that a compound will solve the problem. Those replies contain no demonstrated ACE-083 result. Reddit · moreplatesmoredates and Biohacking cross-post
Bigger muscle and useful strength are separate goals. A Peptides commenter argues that disappointing disease-trial results might still leave cosmetic potential in healthy lifters. That is an opinion, not a successful bodybuilding experiment; it does not demonstrate stronger lifts or useful lasting growth. Reddit · Peptides

Doses people report

These are separate accounts of products labelled ACE-083, not an established range or instructions. mg means milligrams; IM means into muscle.

1 mg every two weeks in a 2023 forum account. The poster does not specify the ACE-083 route or report an attributable result. Their authenticity concern and extensive co-use limit interpretation. Personal report
A biceps log changed its stated plan. The opening proposes 1 mg/week alongside testosterone 300 mg/week, both split twice weekly. The December 8 update instead reports 1 mg IM per biceps, 2 mg total that day, with another administration planned 14 days later. These are not the same schedule. Personal report
40 mg in an adverse-reaction account. A different commenter describes this amount at first use, without specifying route. It belongs to an adverse report, not evidence that larger amounts work better. Reddit · Peptides

Half-life

No dependable community human value. Half-life asks how quickly the measured amount falls by half. The community record does not establish that value for ACE-083. A repeat schedule cannot supply it; the preserved comparison warns against importing a 19-day FLGR number. Community

Onset: when anything is noticed

Soreness after use; growth onset remains unknown. The biceps author reports a bruised feeling after first use that remains overnight, without a measured start date for muscle growth or strength improvement. Personal report

Duration: symptoms versus results

No established lasting benefit in these accounts. The severe-reaction commenter says symptoms improved after two to three hours. That symptom history does not measure benefit duration or whether muscle gained during use persists after stopping. Reddit · Peptides

Cycles and repeat use

Repeat intentions, without a completed course. Fortnightly use or a planned repeat does not establish total course length, time off or a post-stop result. Neither account supplies those answers. Clinical treatment periods cannot supply a bodybuilding cycle. Personal report Personal report Community

What to watch for

A local design does not guarantee a mild reaction. The 40 mg commenter describes severe shaking, chills and high temperature, then questions authenticity. This cannot prove whether genuine ACE-083, contamination or something else caused the reaction. Their later improvement does not establish safety. Reddit · Peptides
The trials reported immune responses and local problems. Antibodies recognizing the study drug appeared in 39.3% of ACE-083 recipients in the FSHD double-blind phase and 47.8% in CMT. FSHD also recorded swelling, pain and nerve symptoms. These findings do not establish why an online user reacted. Official context Official context
Stack safety and long-term use remain unresolved. The FSHD trial excluded pregnancy and use of androgens or growth hormone. Its supervised findings cannot certify those combinations, pregnancy use or prolonged unsupervised use. Official context

From community discussion

A use claim can still leave identity and results unanswered. The 2023 forum author's doubt about legitimacy accompanies the fortnightly amount. They also describe IGF-1 products, growth hormone and treatment for high blood sugar. No isolated ACE-083 result follows in the inspected posts; a board representative's enthusiasm is separate advocacy. Personal report
The biceps update is one person, not corroboration. The same day-one update appears in the post and a comment. Later readers ask for a conclusion, but no outcome is visible. Another reply identifies testosterone as a confounder. Reported formulation difficulty adds uncertainty rather than a preparation method. Personal report
Early excitement included only a secondhand positive claim. In 2014, a MuscleChemistry member said a friend got decent results using 1 mg each of follistatin and an unspecified “ace.” Frequency, route, measurements and product identity were absent. Nearby seller promotion and animal-growth discussion do not turn this into verified ACE-083 success. MuscleChemistry
The comparison with FLGR still has a useful limit. The preserved discussion uses ACE-083 as a human-trial comparison for follistatin-class claims. It does not make the constructs equivalent. Trial disappointment, a different product's marketing and unverified gym anecdotes answer different questions; none supplies a conversion formula. Community

The clinical numbers behind the conversation

Trial milligrams belonged to defined muscles and patients. FSHD dose-escalation used 150 or 200 mg per muscle; biceps also tested 240 mg. Randomized treatment used 240 mg per muscle every three weeks for six months before open-label treatment. Official context
Size and everyday function did not reliably improve together. The CMT study increased volume but lacked broad motor or quality-of-life benefit. Its development program was discontinued, as was FSHD's. This does not resolve healthy-lifter outcomes. Official context Official context
Mostly unmeasurable blood drug is not a muscle half-life. Healthy-volunteer serum testing supported low systemic exposure. It did not establish how long drug remained inside the muscle or a community benefit window. Official context